Ruxolitinib for Emergency Treatment of COVID‐19–Associated Cytokine Storm: Findings From an Expanded Access Study

Ruxolitinib for Emergency Treatment of COVID‐19–Associated Cytokine Storm: Findings From an Expanded Access Study

ABSTRACT Introduction This expanded access program (EAP) provided ruxolitinib (oral, selective Janus kinase [JAK]1/JAK2 inhibitor) for emergency treatment of COVID‐19–associated cytokine storm in patients eligible for hospitalization (NCT04355793). Methods Patients received ruxolitinib 5 mg twice da...

Full description

Saved in:
Bibliographic Details
Main Authors: Jeffrey Weinstein, Nikhil Jagan, Shawnta Lorthridge‐Jackson, J. E. Hamer‐Maansson, Peg Squier
Format: Article
Language:English
Published: Wiley 2025-04-01
Series:The Clinical Respiratory Journal
Subjects:
acute respiratory distress syndrome
COVID‐19
cytokine release syndrome
expanded access
hospitalization
Janus kinase inhibitors
Online Access:https://doi.org/10.1111/crj.70050
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1111/crj.70050

Similar Items